Loading clinical trials...
Loading clinical trials...
Role of Glucagon-Like Peptide-1 (GLP-1) in Congenital Hyperinsulinism: Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
Conditions
Interventions
Exendin (9-39)
Vehicle
Locations
1
United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Start Date
August 26, 2009
Primary Completion Date
January 28, 2017
Completion Date
January 28, 2017
Last Updated
June 1, 2020
NCT02021604
NCT04538989
NCT00674440
NCT01468454
NCT03042416
NCT03053284
Lead Sponsor
Diva De Leon
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions